Market Place
Sourcing Support
TransCode Therapeutics Announces Nasdaq to Regain Compliance
05 Nov 2024 //
GLOBENEWSWIRE
TransCode Therapeutics Phase 1 Trial Cohort 2 Approved
23 Oct 2024 //
GLOBENEWSWIRE
TransCode Complete Dosing 1st Cohort in Ph 1, microRNA Technology
10 Oct 2024 //
GLOBENEWSWIRE
TransCode Announces Treats First Patients in Phase 1 Trial
17 Sep 2024 //
GLOBENEWSWIRE
TransCode Publishes Study On Lead Cancer Therapeutic
10 Sep 2024 //
GLOBENEWSWIRE
TransCode Therapeutics Awarded $2 Million NIH Grant
05 Sep 2024 //
GLOBENEWSWIRE
TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
15 Aug 2024 //
GLOBENEWSWIRE
TransCode Therapeutics, Inc. Announces Closing of Public Offering
24 Jul 2024 //
GLOBENEWSWIRE
TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
22 Jul 2024 //
GLOBENEWSWIRE
TransCode Therapeutics, Inc. Announces Pricing of Public Offering
22 Jul 2024 //
GLOBENEWSWIRE
Nasdaq Says TransCode Regained Listing Compliance Requirements
10 Jun 2024 //
GLOBENEWSWIRE
TransCode Reports Positive First-In-Human Data For TTX-MC138
29 May 2024 //
GLOBENEWSWIRE
TransCode Therapeutics Open Letter to Shareholders
13 May 2024 //
GLOBENEWSWIRE
TransCode Gets FDA Clearance For TTX-MC138 Phase 1/2
15 Apr 2024 //
GLOBENEWSWIRE
TransCode Therapeutics Reports 2023 Results; Provides Business Update
03 Apr 2024 //
GLOBENEWSWIRE
TransCode Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
28 Mar 2024 //
GLOBENEWSWIRE
TransCode and Akribion Report Progress Developing CRISPR-Derived Technology
11 Mar 2024 //
GLOBENEWSWIRE
TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
06 Mar 2024 //
GLOBENEWSWIRE
TransCode Reports Publication of Patent Covering RIG-I Agonist Immunotherapeutic
20 Feb 2024 //
GLOBENEWSWIRE
Nasdaq Determines TransCode Compliance with Stockholders™ Equity Requirement
31 Jan 2024 //
GLOBENEWSWIRE
TransCode Therapeutics and Debiopharm Announce Collaboration
29 Jan 2024 //
GLOBENEWSWIRE
TransCode Therapeutics Announces Closing of $7.25 Million Public Offering
22 Jan 2024 //
GLOBENEWSWIRE
TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering
18 Jan 2024 //
GLOBENEWSWIRE
TransCode Therapeutics Reports Further Restructuring
12 Jan 2024 //
GLOBENEWSWIRE
TransCode Therapeutics Announces 1-for-40 Reverse Stock Split
11 Jan 2024 //
GLOBENEWSWIRE
TransCode Publishes Open Letter Outlining Company™s Progress and Objectives
04 Jan 2024 //
GLOBENEWSWIRE
TransCode Reports PositiveResults in Metastatic Pancreatic Cancer with TTX-MC138
12 Dec 2023 //
GLOBENEWSWIRE
TransCode To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium
05 Dec 2023 //
GLOBENEWSWIRE
TransCode Announces Closing of $1.2M Direct Offering of Common Stock
04 Dec 2023 //
GLOBENEWSWIRE
TransCode Announces $1.2 Million Registered Direct Offering of Common Stock
30 Nov 2023 //
GLOBENEWSWIRE
TransCode Therapeutics Reports Third Quarter 2023 Results
14 Nov 2023 //
GLOBENEWSWIRE
TransCode Therapeutics Withdraws Public Offering
30 Oct 2023 //
GLOBENEWSWIRE
Nasdaq Panel Grants TransCode Extension for Continued Listing on The Nasdaq
27 Oct 2023 //
GLOBENEWSWIRE
TransCode Announces Prolonged Survival in Murine Models with Glioblastoma
26 Oct 2023 //
GLOBENEWSWIRE
TransCode Therapeutics Announces Public Offering of Common Stock
26 Oct 2023 //
GLOBENEWSWIRE
TransCode Therapeutics Announces Preliminary Clinical Results in TTX-MC138
24 Oct 2023 //
GLOBENEWSWIRE
TransCode Reports Successful Treatment of Preclinical Melanoma Tumors
16 Oct 2023 //
GLOBENEWSWIRE
TransCode Therapeutics Announces Closing of $8.5 Million Public Offering
28 Sep 2023 //
GLOBENEWSWIRE
TransCode Announces Positive Pre-Clinical Glioblastoma Results with TTX-MC138
25 Sep 2023 //
GLOBENEWSWIRE
TransCode Therapeutics Announces Pricing of $8 Million Public Offering
25 Sep 2023 //
GLOBENEWSWIRE
TransCode Announces First Subject Dosed with TTX-MC138 in First-In-Human Trial
23 Aug 2023 //
GLOBENEWSWIRE
TransCode Reports Second Quarter 2023 Results; Provides Business Update
14 Aug 2023 //
GLOBENEWSWIRE
TransCode Announces Positive Results in Non-human Primates with TTX-MC138
31 Jul 2023 //
GLOBENEWSWIRE
TransCode Therapeutics CEO Letter to Shareholders
05 Jul 2023 //
GLOBENEWSWIRE
TransCode Announces Publication of New Data Supporting the Use of TTX-MC138
22 Jun 2023 //
GLOBENEWSWIRE
TransCode Therapeutics Announces Closing of $7 Million Public Offering
09 Jun 2023 //
PRESS RELEASE
TransCode Reports Positive Results with its Lead Candidate, TTX-MC138
06 Jun 2023 //
GLOBENEWSWIRE
TransCode Therapeutics Announces Pricing of $7 Million Public Offering
06 Jun 2023 //
GLOBENEWSWIRE
TransCode Therapeutics Announces 1-for-20 Reverse Stock Split
22 May 2023 //
GLOBENEWSWIRE
TransCode Announces IRB Approval for FDA Cleared First-In-Human Clinical Trial
27 Apr 2023 //
GLOBENEWSWIRE
TransCode Therapeutics Announces Strategic Expansion of its Product Portfolio
26 Apr 2023 //
GLOBENEWSWIRE
TransCode Announces Equity Investment from White Lion Capital
14 Apr 2023 //
GLOBENEWSWIRE
TransCode Therapeutics to present at AACR Annual Meeting 2023
06 Apr 2023 //
GLOBENEWSWIRE
TransCode Therapeutics Receives Notice of Award from NIH for TTX-MC138
05 Apr 2023 //
GLOBENEWSWIRE
TransCode Announces Termination of Announced Sale of Series A Preferred Stock
04 Apr 2023 //
GLOBENEWSWIRE
TransCode Announces Agreement with Triton Funds for Sale of Preferred Stock
03 Apr 2023 //
GLOBENEWSWIRE
TransCode Therapeutics Reports 2022 Results; Provides Business Update
31 Mar 2023 //
GLOBENEWSWIRE
TransCode Therapeutics Announces Orphan Drug Designation Status for TTX-MC138
28 Feb 2023 //
GLOBENEWSWIRE
TransCode and BRAIN join forces to develop a CRISPR-derived technology platform
22 Feb 2023 //
GLOBENEWSWIRE
TransCode Announces Closing of $1.5M Registered Direct Offering of Common Stock
17 Feb 2023 //
GLOBENEWSWIRE
